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On 4 May 2016, the evidence-based ’2016 European 
Guideline on the management of non-gonococcal ure-
thritis’ was published online [1]. This guideline is a 
comprehensive updated version of the European guide-
line from 2009 [2] and provides up-to-date and detailed 
guidance regarding aetiology, clinical features, diag-
nosis, testing, treatment and general management of 
symptomatic non-gonococcal urethritis in Europe.
The most common organisms implicated are Chlamydia 
trachomatis and Mycoplasma genitalium, with the lat-
ter perhaps causing more symptoms [3]. Testing male 
patients with urethritis for M. genitalium, preferably 
with screening for macrolide resistance, is highly likely 
to improve clinical outcomes [4]. Testing symptomatic 
patients for M. genitalium is therefore recommended.
Of major concern is the increasing azithromycin resist-
ance of M. genitalium [5]. Azithromycin, especially 
single dosage of 1 g, is associated with the develop-
ment of macrolide resistance in M. genitalium, and is 
likely to increase the circulation of macrolide-resistant 
strains in the population [5]. Consequently, single dose 
azithromycin is no longer recommended as first-line 
treatment for non-gonococcal urethritis.
Updates to the guideline include recommendations on 
the diagnosis, testing and treatment of non-gonococ-
cal urethritis:
Urethritis should be confirmed by urethral smear 
microscopy in symptomatic patients.
• Symptoms and negative urethral smear: No empiri-
cal treatment. Re-attend for early morning smear if 
nucleic acid amplification testing (NAAT) was nega-
tive and symptoms do not settle.
• All men assessed for sexually transmitted infec-
tions, regardless of symptoms, should be tested for 
C. trachomatis from a first-void urine specimen and 
for Neisseria gonorrhoeae if they have urethritis. If a 
NAAT is positive for gonorrhoea, a culture should be 
performed before treatment.
• All men who have sex with men should be tested for 
both C. trachomatis and N. gonorrhoeae from any 
potentially exposed site.
• Recommended syndromic regimen: doxycycline 
100 mg twice daily for seven days. Azithromycin 1 g 
immediately should not be used routinely because 
of the increased risk of inducing macrolide antimi-
crobial resistance with M. genitalium.
• If M. genitalium-positive: azithromycin 500 mg 
immediately, followed by a 250 mg oral dose for four 
days. A test of cure three to five weeks after treat-
ment in those who tested positive for M. genitalium 
should be performed.
In case of persistent and/or recurrent non-gonococcal 
urethritis, testing for M. genitalium using a NAAT, pref-
erably with screening for macrolide resistance, should 
be considered, as well as testing for Trichomonas vagi-
nalis using a NAAT if it is prevalent in the local popula-
tion. Recurrent non-gonococcal urethritis should only 
be treated if the patient has definite symptoms of ure-
thritis, or if there are physical signs and microscopic 
evidence of urethritis on examination.
The guidelines are available here
40 www.eurosurveillance.org
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